Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.

Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.

Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.

Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.

Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.

Healthy

Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min

Dimethyltryptamine (DMT)

Intravenous saline bolus and/or saline maintenance perfusion over 90 min

Saline

Effects of Dimethyltryptamine in Healthy Subjects

Effects of Dimethyltryptamine (DMT) in Healthy Subjects: A Placebo-controlled Cross-over Study

Assessed once on each study day via 5 Dimensions of Altered States of Consciousness (5D-ASC) scale consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects

Assessed 22 times on each study day via Subjective Effect Scale (SES), consisting of 4 questions to be rated on a Likert scale ranging from 1 to 10, with higher ratings indicating stronger effects

Assessed twice on each study day via the Adjective Mood Rating Scale (AMRS) consisting of 60 items to be rated on a 4-point Likert scale, with higher ratings indicating stronger identification with the specific mood

Assessed once on each study day via States of Consciousness Questionnaire (SCQ) which measures the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")

Assessed 22 times on each study day via systolic and diastolic blood pressure, Emax

Assessed 22 times on each study day via heart rate, Emax

Assessed 21 times on each study day via blood samples

Assessed twice on each study day via blood samples

Collected once per study day via one-time interval urine recovery

Assessed via NEO-Five-Factor-Inventory (NEO-FFI)

Assessed via Freiburger Personality Inventory (FPI)

Assessed via Saarbrücker Personality Questionnaire (SPF)

Assessed via Elliot Humility Scale (EHS) which measures the personality trait humility through 13 items on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree"

Assessed via Jankowski Humility Scale (JHS) which measures the personality trait humility through 18 items on a 5-point Likert scale ranging from "not at all" to "strongly"

Assessed via Arnett Inventory of Sensation Seeking (AISS-d)

Assessed via Defense Style Questionnaire (DSQ-40)

Assessed via the List of Complaints (LC) which covers the emergence of 66 complaints in a yes/no format

University Hospital, Basel, Switzerland

Double-blind, placebo-controlled, 5-period cross-over design with 4 different doses of DMT and placebo

Major Depression

patients will receive a single dose of ayahuasca.

Ayahuasca

patients will receive a single dose of a passive placebo.

placebo

Draulio B de Araujo

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

changes in depression severity, assessed by HAM-D scale, from baseline to 7 days after dosing

changes in depression severity, assessed by MADRS scale, from baseline to 1 day, 2 days, and 7 days after dosing

response rate: reduction of 50% or more in baseline scores, assessed seven days after dosing by the HAM-D scale.

response rate: reduction of 50% or more in baseline scores, assessed at one day, two days and seven days after dosing by the MADRS scale.

banisteriopsis variabilis/pretsēnīšu

Effects of Dimethyltryptamine in Healthy Subjects

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne